Incentives to Innovate

The Oxford Handbook of the Economics of the Biopharmaceutical Industry

Volumn , Issue , 2012, Pages

  Lakdawalla, Darius N ^a,b   Sood, Neeraj ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Canonical positive model; Innovation; Innovative activity; Normative theory; Social value

Indexed keywords

EID: 85066546513     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780199742998.013.0006     Document Type: Chapter

References (58)

1. Arora, A., M. Ceccagnoli, and W.M. Cohen. 2003. R&D and the Patent Premium. NBER Working Paper 9431. Cambridge, MA: National Bureau of Economic Research.
2. Acemoglu, D., and J. Linn. 2004. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry." Quarterly Journal of Economics 119(3): 1049-1090.
3. Albainy-Jenei, S. 2006. "Claim Construction and the Doctrine of Equivalents in Amgen v Transkaryotic Therapies, Inc." Journal of Intellectual Property Law Practice 1(13): 819-821.
4. Berndt Ernst R., Adrian H. B. Gottschalk, Tomas Philipson, and Matthew W. Strobeck. 2005. "Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process," Forum for Health Economics & Policy. Vol. 8: (Frontiers in Health Policy Research), Article 2. http://www.bepress.com/fhep/8/2.
5. Blume-Kohout, M. 2009. Drug Development and Public Research Funding: Evidence of Lagged Effects. RAND working paper. Santa Monica, CA: RAND Corporation.
6. Blume-Kohout, M., and N. Sood. 2009. Medicare Part D and Pharmaceutical R&D. RAND Working Paper. Santa Monica, CA: RAND Corporation.
7. Blume-Kohout, M.E., K.B. Kumar, and N. Sood (2009). Federal Life Sciences Funding and University R&D. NBER Working Paper 15146. Cambridge, MA: National Bureau of Economic Research.
8. Boldrin, M., and D.K. Levine. 2002. "The Case against Intellectual Property." American Economic Review 92(2): 209-212.
9. Brekke, K.R., A.L. Grasdal, and T.H. Holmas. 2009. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?" European Economic Review 53(2): 170-185.
10. Comanor, W.S. 1986. "The Political Economy of the Pharmaceutical Industry." Journal of Economic Literature (24): 1178-1217.
11. Congressional Budget Office. 2006. Medical Malpractice Tort Limits and Health Care Spending. Washington, DC: Government Printing Office.
12. Danzon, P.M., and L. Chao. 2000. "Does Regulation Drive Out Competition in Pharmaceutical Markets?" Journal of Law and Economics 43(2): 311-357.
13. Duggan, M., and F.S. Morton. 2008. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization." NBER Working Paper 13917. Cambridge, MA: National Bureau of Economic Research.
14. Duggan, M., and F.S. Morton. 2010. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization." American Economic Review 100(1): 590-607.
15. Ekelund, M., and B. Persson. 2003. "Pharmaceutical Pricing in a Regulated Market." Review of Economics and Statistics 85(2): 298-306.
16. Encaoua, D., D. Guellec, and C. Martinez. 2006. "Patent Systems for Encouraging Innovation: Lessons from Economic Analysis." Research Policy 35(9): 1423-1440.
17. Finkelstein, A. 2004. "Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry." Quarterly Journal of Economics 119(2): 527-564.
18. Gallini, N. 1992. "Patent Policy and Costly Imitation." RAND Journal of Economics 23: 52-63.
19. Gilbert, R., and C. Shapiro. 1990. "Optimal Patent Length and Breadth." RAND Journal of Economics 21: 106-112.
20. Grabowski, H. 1968. "The Determinants of Industrial Research and Development: A Study of the Chemical, Drug and Petroleum Industries." Journal of Political Economy (76): 292-306.
21. Grabowski, H., and J. Vernon. 2000. "The Determinants of Pharmaceutical Research and Development Expenditures." Journal of Evolutionary Economics 10(1-2): 201-215.
22. Heller, M.A., and R.S. Eisenberg. 1998. "Can Patents Deter Innovation? The Anticommons in Biomedical Research." Science 280(5364): 698-701.
23. Hicks, J. 1932. The Theory of Wages. London: Macmillan.
24. Hubbard, R.G. 1998. "Capital-Market Imperfections and Investment." Journal of Economic Literature 36(1): 193-225.
25. Kessler, D.P. 2005. "The Effects of Pharmaceutical Price Controls on the Cost and Quality of Medical Care: A Review of the Empirical Literature." Annex C, PhRMA Submission to the US Department of Commerce, July 1, 2004. Available at http://www.ita.doc.gov/td/health/phRMA/PhRMA%20-%20ANNEX%20C.pdf (accessed November 2011).
26. Kremer, M. 1998. "Patent Buyouts: A Mechanism for Encouraging Innovation." Quarterly Journal of Economics 113(4): 1137-1167.
27. Kremer, M. 2001a. "Creating Markets for New Vaccines-Part I: Rationale." In Innovation Policy and the Economy. Vol. 1. Edited by A. B. Jaffe, J. Lerner, and S. Stern, 35-72. Cambridge, MA: MIT Press.
28. Kremer, M. 2001b. "Creating Markets for New Vaccines-Part II: Design Issues." In Jaffe, Lerner, and Stern, Innovation Policy and the Economy. Vol. 1. 73-118.
29. Kremer, M., and C. Snyder. 2006. "Why Is There No AIDS Vaccine?" Working Paper. Cambridge, MA: Harvard University. Available at http://www.economics.harvard.edu/faculty/kremer/files/vac36_9June06.pdf.
30. Kyle, M., and A. McGahan. 2009. "Investments in Pharmaceuticals Before and After TRIPS." NBER Working Paper 15468. Cambridge, MA: National Bureau of Economic Research.
31. Lakdawalla, D., and N. Sood. 2004. "Social Insurance and the Design of Innovation Incentives." Economics Letters 85(1): 57-61.
32. Lakdawalla, D., and N. Sood. 2006. "Health Insurance as a Two-Part Pricing Contract." NBER Working Paper 12681. Cambridge, MA: National Bureau of Economic Research.
33. Lakdawalla, D., and N. Sood. 2009. "Innovation and the Welfare Effects of Public Drug Insurance." Journal of Public Economics 93: 541-548.
34. Lee, T., and L.L. Wilde. 1980. "Market Structure and Innovation: A Reformulation." Quarterly Journal of Economics 94(2): 429-436.
35. Lichtenberg, F.R., and J. Waldfogel. 2003. "Does Misery Love Company? Evidence From Pharmaceutical Markets Before and After the Orphan Drug Act." NBER Working Paper 9750. Cambridge, MA: National Bureau of Economic Research.
36. Llobet, G., H. Hopenhayn, and M. Mitchell. 2000. "Rewarding Sequential Innovators: Prizes, Patents and Buyouts." Staff Report 273. Minneapolis, MN: Federal Reserve Bank of Minneapolis.
37. Loury, G.C. 1979. "Market Structure and Innovation." Quarterly Journal of Economics 93(3): 395-410.
38. Mansfield, E. 1986. "Patents and Innovation: An Empirical Study." Management Science 32(2): 173-181.
39. Mansfield, E., M. Schwartz, and S. Wagner. 1981. "Imitation Costs and Patents: An Empirical Study." Economic Journal 91(364): 907-918.
40. Martikainen, J., I. Kivi, and I. Linnosmaa. 2005. "European Prices of Newly Launched Reimbursable Pharmaceuticals: A Pilot Study." Health Policy 74(3): 235-246.
41. McCutchen, W. 1993. "Estimating the Impact of the R&D Tax Credit on Strategic Groups in the Pharmaceutical Industry." Research Policy 22(4): 337-351.
42. Menell, P.S., and S. Scotchmer. 2007. "Intellectual Property Law." In Handbook of Law and Economics. Vol. 2. Edited by A.M. Polinsky and S. Shavell, 1473-1570. New York: Elsevier.
43. Nelson, R.R., and S.G. Winter. 1982. An Evolutionary Theory of Economic Change. Cambridge, MA, Belknap Press of Harvard University Press.
44. Nordhaus, W. 1969. Invention, Growth and Welfare. Cambridge, MA: MIT Press.
45. Nordhaus, W. 2004. "Schumpeterian Profits in the American Economy: Theory and Measurement." NBER Working Paper 10433. Cambridge, MA: National Bureau of Economic Research.
46. O'Donoghue, T., S. Scotchmer, and J.-F. Thisse. 1998. "Patent Breadth, Patent Life, and the Pace of Technological Progress." Journal of Economics and Management Strategy 7(1): 1-32.
47. Oi, W.Y. 1971. "A Disneyland Dilemma: Two-Part Tariffs for a Mickey Mouse Monopoly." Quarterly Journal of Economics 85: 77-96.
48. Pavcnik, N. 2002. "Do Pharmaceutical Prices Respond to Potential Out-of-Pocket Expenses?" RAND Journal of Economics 33(3): 469-487.
49. Pekurinen, M., and U. Hakkinen. 2005. "Regulating Pharmaceutical Markets in Finland." Discussion Papers, vol. 4-2005. Helsinki, Finland: STAKES, National Research and Development Centre for Health Economics.
50. Philipson, T.J., and A.B. Jena. 2006. "Surplus Appropriation from R&D and Health Care Technology Assessment Procedures." NBER Working Paper 12016. Cambridge, MA: National Bureau of Economic Research.
51. Scherer, F.M. 2001. "The Link Between Gross Profitability and Pharmaceutical R&D Spending." Health Affairs 20(5): 216-220.
52. Scotchmer, S. 1999. "On the Optimality of the Patent Renewal System." RAND Journal of Economics 30(2): 181-196.
53. Sood, N., H. de Vries, I. Gutierrez, D.N. Lakdawalla, and D.P. Goldman. 2009. "The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries." Health Affairs (Millwood) 28(1): w125-w137.
54. Toole, A.A. 2007. "Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry?" Journal of Law & Economics 50(1): 81-104.
55. US Department of Commerce. 2004. "Pharmaceutical Price Controls in OECD Countries: Implications for U. S. Consumers, Pricing, Research and Development, and Innovation." Washington, DC: International Trade Administration.
56. Vernon, J.A. 2005. "Examining the Link Between Price Regulation and Pharmaceutical R&D Investment." Health Economics 14(1): 1-16.
57. Williams, H. 2010. Intellectual Property Rights and Innovation: Evidence From the Human Genome. NBER Working Paper No. 216213. Cambridge, MA: National Bureau of Economic Research.
58. Yin, W. 2008. "Market Incentives and Pharmaceutical Innovation." Journal of Health Economics 27(4): 1060-1077.